• Tech
• Gadgets
• Mobile
• Enterprise
• CrunchBase
• More
  • Beta Invites
  • Elevator Pitches
  • Gillmor Gang
  • Podcasts
  • TechCrunch50
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

HBM BioVentures

edit

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures’ portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

Milestones

edit

• 
  HBM BioVentures invested in Probiodrug. (11/2/09)
  Posted 11/3/09 at 1:20am
• 
  HBM BioVentures invested in Kolltan Pharmaceuticals. (10/12/09)
  Posted 10/12/09 at 5:58pm
• 
  HBM BioVentures invested in Lux Biosciences. (10/09)
  Posted 10/19/09 at 5:47pm
• 
  HBM BioVentures invested in Nabriva Therapeutics. (10/09)
  Posted 10/28/09 at 6:21pm
• 
  HBM BioVentures invested in Zosano Pharma. (8/6/09)
  Posted 8/6/09 at 10:23am
• 
  HBM BioVentures invested in ESBATech. (8/7/08)
  Posted 6/24/09 at 12:46am
• 
  HBM BioVentures invested in Pelikan Technologies. (12/6/07)
  Posted 9/14/09 at 6:40am
• 
  HBM BioVentures invested in Zosano Pharma. (11/15/07)
  Posted 7/14/09 at 3:46am
• 
  HBM BioVentures invested in ChemoCentryx. (3/22/07)
  Posted 9/12/09 at 9:14am
• 
  HBM BioVentures invested in ChemoCentryx. (6/17/04)
  Posted 7/23/09 at 8:08pm
• 
  HBM BioVentures invested in Broncus Technologies, Inc. .
  Posted 1/23/09 at 8:49pm

Investments

Videos

Sources

1. Probiodrug Closes Series B Financing Round exceeding EUR 36 Million (US$54 Million) (probiodrug.de) [edit]
2. Kolltan Pharmaceuticals, Inc.: Series A $5M (onbiovc.com) [edit]
3. Lux Biosciences scores $50M Series B for eye cure (venturebeat.com) [edit]
4. Nabriva hauls in $22M in fresh VC funds (fiercebiotech.com) [edit]
5. Zosano Pharma, Inc.: Series B $30M (onbiovc.com) [edit]
6. ESBATech rounds up $22M in second round (fiercebiotech.com) [edit]
7. Pelikan Tech to push “finger friendly” diabetes testing (venturebeat.com) [edit]
8. Zosano Pharma, Inc. Announces Funding Close Totaling $90 Million (zosanopharma.com) [edit]
9. ChemoCentryx, autoimmune disease drug co., raises $29.84M (deals.venturebeat.com) [edit]
10. ChemoCentryx Raises $33 Million in Private Financing (chemocentryx.com) [edit]
11. Broncus Technologies lines up venture debt financing for emphysema treatment (venturebeat.com) [edit]